← Back to Clinical Trials
Recruiting NCT06112509

NCT06112509 Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife Radio-surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06112509
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Besancon
Condition Vestibular Schwannoma
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2024-02-20
Primary Completion 2024-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Vestibular exam

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2024-02-20 with a primary completion date of 2024-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate the vestibular effects of gamma-knife radiosurgery, as part of the treatment of vestibular schwannoma.

Eligibility Criteria

Inclusion Criteria : * Men and women aged 18 to 90 included * Subject who benefited from gamma-knife radiosurgery as part of the treatment of vestibular schwannoma * Non-opposition of the subject to participate in the study * Affiliation to a French social security scheme or beneficiary of such a scheme Exclusion Criteria : * Subject with another vestibular pathology * Subject who did not benefit from a vestibular assessment before treatment with gamma-knife radiosurgery * Legal incapacity or limited legal capacity * Subject unlikely to cooperate in the study and/or weak cooperation anticipated by the investigator * Subject without health insurance * Subject being in the period of exclusion from another study or provided for by the "national volunteer file".

Contact & Investigator

Central Contact

Mylene ABISSE, MD

✉ mabisse@chu-besancon.fr

📞 +33381218988

Principal Investigator

DAMON Veronique, MD

PRINCIPAL INVESTIGATOR

CHU de Besançon

Frequently Asked Questions

Who can join the NCT06112509 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Vestibular Schwannoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06112509 currently recruiting?

Yes, NCT06112509 is actively recruiting participants. Contact the research team at mabisse@chu-besancon.fr for enrollment information.

Where is the NCT06112509 trial being conducted?

This trial is being conducted at Besançon, France.

Who is sponsoring the NCT06112509 clinical trial?

NCT06112509 is sponsored by Centre Hospitalier Universitaire de Besancon. The principal investigator is DAMON Veronique, MD at CHU de Besançon. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology